欧洲神经科学协会联盟/周围神经学会 (EFNS/PNS) 标准[40]Van den Bergh PY, Hadden RD, Bouche P, et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - first revision. Eur J Neurol. 2010 Mar;17(3):356-63.http://www.efns.org/fileadmin/user_upload/guidline_papers/EFNS_guideline_2010_inflammatory_demyelinating_polyradiculoneuropathy.pdfhttp://www.ncbi.nlm.nih.gov/pubmed/20456730?tool=bestpractice.com
多项临床诊断、电生理学和实验室标准具有不同程度的敏感性和特异性。[1]Dyck PJ, Lais AC, Ohta M, et al. Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc. 1975 Nov;50(11):621-37.http://www.ncbi.nlm.nih.gov/pubmed/1186294?tool=bestpractice.com[3]Barohn RJ, Kissel JT, Warmolts JR, et al. Chronic inflammatory demyelinating polyradiculoneuropathy: clinical characteristics, course, and recommendations for diagnostic criteria. Arch Neurol. 1989 Aug;46(8):878-84.http://www.ncbi.nlm.nih.gov/pubmed/2757528?tool=bestpractice.com[40]Van den Bergh PY, Hadden RD, Bouche P, et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - first revision. Eur J Neurol. 2010 Mar;17(3):356-63.http://www.efns.org/fileadmin/user_upload/guidline_papers/EFNS_guideline_2010_inflammatory_demyelinating_polyradiculoneuropathy.pdfhttp://www.ncbi.nlm.nih.gov/pubmed/20456730?tool=bestpractice.com[41]Albers JW, Kelly JJ Jr. Acquired inflammatory demyelinating polyneuropathies: Clinical and electrodiagnostic features. Muscle Nerve. 1989 Jun;12(6):435-51.https://deepblue.lib.umich.edu/handle/2027.42/50143http://www.ncbi.nlm.nih.gov/pubmed/2657418?tool=bestpractice.com[42]Cornblath DR, Asbury AK, Albers JW, et al. Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP): Report from the Ad Hoc Subcommittee of the AAN AIDS Task Force. Neurology. 1991 May;41(5):617-8.http://www.ncbi.nlm.nih.gov/pubmed/2027473?tool=bestpractice.com[43]Hughes R, Bensa S, Willison H, et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 2001 Aug;50(2):195-201.http://www.ncbi.nlm.nih.gov/pubmed/11506402?tool=bestpractice.com[44]Saperstein DS, Katz JS, Amato AA, et al. Clinical spectrum of chronic acquired demyelinating polyneuropathies. Muscle Nerve. 2001 Mar;24(3):311-24.http://www.ncbi.nlm.nih.gov/pubmed/11353415?tool=bestpractice.com[45]Nicolas G, Maisonobe T, Le Forestier N, et al. Proposed revised electrophysiological criteria for chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve. 2002 Jan;25(1):26-30.http://www.ncbi.nlm.nih.gov/pubmed/11754181?tool=bestpractice.com[46]Thaisetthawatkul P, Logigian EL, Herrmann DH. Dispersion of the distal compound muscle action potential as a diagnostic criterion for chronic inflammatory demyelinating polyneuropathy. Neurology. 2002 Nov 26;59(10):1526-32.http://www.ncbi.nlm.nih.gov/pubmed/12451191?tool=bestpractice.com[47]Magda P, Latov N, Brannagan TH, et al. Comparison of electrodiagnostic abnormalities and criteria in a cohort of patients with chronic inflammatory demyelinating polyneuropathy. Arch Neurol. 2003 Dec;60(12):1755-9.http://archneur.jamanetwork.com/article.aspx?articleid=785089http://www.ncbi.nlm.nih.gov/pubmed/14676052?tool=bestpractice.com[48]Van den Bergh PY, Pieret F. Electrodiagnostic criteria for acute and chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve. 2004 Apr;29(4):565-74.http://www.ncbi.nlm.nih.gov/pubmed/15052622?tool=bestpractice.com[49]French CIDP Study Group. Recommendations on diagnostic strategies for chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry. 2008 Feb;79(2):115-8.http://www.ncbi.nlm.nih.gov/pubmed/18202204?tool=bestpractice.com 但是,大多数标准设置的特异性接近 100%,敏感性通常是 60%-70%。 如果结合两组具有不同参数的标准设置,敏感性可能更高。[46]Thaisetthawatkul P, Logigian EL, Herrmann DH. Dispersion of the distal compound muscle action potential as a diagnostic criterion for chronic inflammatory demyelinating polyneuropathy. Neurology. 2002 Nov 26;59(10):1526-32.http://www.ncbi.nlm.nih.gov/pubmed/12451191?tool=bestpractice.com 运动传导阻滞的特异性较高。[107]Cocito D, Chio A, Tavella A, et al. Treatment response and electrophysiological criteria in chronic inflammatory demyelinating polyneuropathy. Eur J Neurol. 2006 Jun;13(6):669-70.http://www.ncbi.nlm.nih.gov/pubmed/16796598?tool=bestpractice.com 更多的神经测试可能提高敏感性。[108]Rajabally YA, Jacob S, Hbahbih M. Optimizing the use of electrophysiology in the diagnosis of chronic inflammatory demyelinating polyneuropathy: a study of 20 cases. J Peripher Nerv Syst. 2005 Sep;10(3):282-92.http://www.ncbi.nlm.nih.gov/pubmed/16221287?tool=bestpractice.com 最新和广泛使用的是 EFNS/PNS 指南。[40]Van den Bergh PY, Hadden RD, Bouche P, et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - first revision. Eur J Neurol. 2010 Mar;17(3):356-63.http://www.efns.org/fileadmin/user_upload/guidline_papers/EFNS_guideline_2010_inflammatory_demyelinating_polyradiculoneuropathy.pdfhttp://www.ncbi.nlm.nih.gov/pubmed/20456730?tool=bestpractice.com 与不符合 EFNS/PNS 标准的患者相比,符合这些标准的患者预测可能具有更高的治疗反应率。 然而,这可能不适用于 CIDP 患者和糖尿病患者。[51]Abraham A, Breiner A, Katzberg HD, et al. Treatment responsiveness in CIDP patients with diabetes is associated with unique electrophysiological characteristics, and not with common criteria for CIDP. Expert Rev Clin Immunol. 2015 Apr;11(4):537-46.http://www.ncbi.nlm.nih.gov/pubmed/25764107?tool=bestpractice.com
临床诊断标准
1. 纳入标准:
a. 典型 CIDP
b. 非典型 CIDP
包括以下中的一项,否则如上:
注意:对于非患肢,腱反射可能正常。
2. 排除标准:
接触 Lyme 病、白喉、药物或毒素可能引起神经病
遗传性脱髓鞘神经病可能基于家族史、足畸形、手足残缺、色素性视网膜炎、鱼鳞癣或者易患压迫性麻痹
主要括约肌紊乱
多灶性运动神经病
髓鞘相关糖蛋白抗体
脱髓鞘性神经病变的其他病因;多神经病变、脏器肿大、内分泌疾病、单克隆免疫球蛋白血症和皮肤变化 (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes, POEMS) 综合征、骨硬化性骨髓瘤、淋巴瘤、淀粉样变性、腰骶神经根神经病变。
电诊法标准
1. 确诊 CIDP
至少包括以下一项:
在 2 条神经中,超过 50% 的运动远端潜伏期延长达正常上限 (ULN)
在 2 条神经中,超过 30% 的运动传导速度减慢至正常下限 (LLN)
在 2 条神经中,超过 30% 的 F 波潜伏期延长达 ULN(如果远端复合肌肉动作电位 [CMAP] 波幅小于 80% 的 LLN,则超过 50% )
如果远端 CMAP 波幅大于 20% 的 LLN,在 2 条神经中 F 波不存在,在另一条神经中至少加 1 项其他脱髓鞘参数
如果在 2 条神经中远端 CMAP 波幅大于 20% 的 LLN,在近端至远端负峰 CMAP 波幅中,局部运动传导阻滞大于 50%,或者在另一条神经中至少加 1 项其他脱髓鞘参数
在至少 2 条神经中,异常时间离散大于 30% 的近端和远端负峰 CMAP之间的持续时间增加
在 1 条神经中,至少 9 ms 的远端 CMAP 持续时间,在另一条神经中至少加 1 项其他脱髓鞘参数。
2. 疑诊 CIDP:
3. CIDP 可能:
支持标准
脑脊液蛋白升高伴有白细胞计数<10 个/mm^3
磁共振成像提示钆增强,和/或马尾神经、腰骶神经根或颈神经根或者臂神经丛或腰骶神经丛肥大
在 5 条或更多条纤维或多于 6/50 条单纤维中采用电子显微镜检查,神经活检提示脱髓鞘和/或髓鞘再生的明确证据
免疫调节剂治疗之后客观的临床改善
在至少 1 条神经中的异常感觉电生理学:(a) 正常腓肠神经伴异常正中神经(排除腕管综合征)或桡骨感觉神经动作电位 (SNAP) 波幅;或者 (b) 传导速度小于 80% 的 LLN(如果 SNAP 波幅小于 80%的LLN,则 小于 70%);或者 (c) 延迟体感诱发电位不伴有中枢神经系统疾病。
进行检查以发现并发病
诊断分类
1. 确诊 CIDP:
2. 疑诊 CIDP:
3. CIDP 可能:
4. CIDP(确诊、疑诊、可能)和并发疾病。